NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Clinical trials for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye injection shows promise for common vision loss conditions
Disease control CompletedThis early-stage study tested the safety of two different versions of an experimental eye injection called OLN324. The trial involved 164 adults with either wet age-related macular degeneration or diabetic macular edema, two conditions that can cause vision loss. Researchers want…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE1 • Sponsor: Ollin Biosciences, Inc. • Aim: Disease control
Last updated Apr 02, 2026 06:56 UTC
-
New Vision-Saving injection challenges standard treatment in major eye disease trial
Disease control CompletedThis study tested if a new eye injection called BAT5906 works as well as the established drug Lucentis to control wet age-related macular degeneration (AMD), a leading cause of vision loss. Nearly 500 patients received monthly injections of either BAT5906 or Lucentis for a year t…
Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC